New Indian moves on pharma pricing

22 December 2014
drugs_pills_tablets_big

Early January 2015, the Indian government is to come out with a new list of life saving drugs whose prices would be controlled. A core committee, under the Director General of the Indian Council for Medical Research has been established to suggest a new list of medicines that can be brought under price control, reports The Pharma Letter’s India correspondent.

In order to keep a check on the price of essential medicines, the Indian government brought 52 new drugs under price control on December 19, including some commonly used painkillers and antibiotics, as also cancer medications.

Monitoring of drug prices has also been intensified in India. Pharmaceutical companies that tend to overcharge drugs listed in the scheduled category as well as outside the controlled category would soon receive more than a rap on their knuckles from the Department of Pharmaceuticals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics